1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Therapeutic Nuclear Medicines Revenue
1.4 Market Analysis by Type
1.4.1 Global Therapeutic Nuclear Medicines Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Radium-223
1.4.3 Lutetium-177
1.4.4 Iodine-131
1.4.5 Other
1.5 Market by Application
1.5.1 Global Therapeutic Nuclear Medicines Market Share by Application: 2021-2026
1.5.2 Thyroid
1.5.3 Bone Metastasis
1.5.4 Lymphoma
1.5.5 Other
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Therapeutic Nuclear Medicines Market
1.8.1 Global Therapeutic Nuclear Medicines Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Therapeutic Nuclear Medicines Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Therapeutic Nuclear Medicines Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Therapeutic Nuclear Medicines Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Therapeutic Nuclear Medicines Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Therapeutic Nuclear Medicines Sales Volume Market Share by Region (2015-2020)
3.2 Global Therapeutic Nuclear Medicines Sales Revenue Market Share by Region (2015-2020)
3.3 North America Therapeutic Nuclear Medicines Sales Volume
3.3.1 North America Therapeutic Nuclear Medicines Sales Volume Growth Rate (2015-2020)
3.3.2 North America Therapeutic Nuclear Medicines Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Therapeutic Nuclear Medicines Sales Volume
3.4.1 East Asia Therapeutic Nuclear Medicines Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Therapeutic Nuclear Medicines Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Therapeutic Nuclear Medicines Sales Volume (2015-2020)
3.5.1 Europe Therapeutic Nuclear Medicines Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Therapeutic Nuclear Medicines Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Therapeutic Nuclear Medicines Sales Volume (2015-2020)
3.6.1 South Asia Therapeutic Nuclear Medicines Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Therapeutic Nuclear Medicines Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Therapeutic Nuclear Medicines Sales Volume (2015-2020)
3.7.1 Southeast Asia Therapeutic Nuclear Medicines Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Therapeutic Nuclear Medicines Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Therapeutic Nuclear Medicines Sales Volume (2015-2020)
3.8.1 Middle East Therapeutic Nuclear Medicines Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Therapeutic Nuclear Medicines Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Therapeutic Nuclear Medicines Sales Volume (2015-2020)
3.9.1 Africa Therapeutic Nuclear Medicines Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Therapeutic Nuclear Medicines Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Therapeutic Nuclear Medicines Sales Volume (2015-2020)
3.10.1 Oceania Therapeutic Nuclear Medicines Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Therapeutic Nuclear Medicines Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Therapeutic Nuclear Medicines Sales Volume (2015-2020)
3.11.1 South America Therapeutic Nuclear Medicines Sales Volume Growth Rate (2015-2020)
3.11.2 South America Therapeutic Nuclear Medicines Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Therapeutic Nuclear Medicines Sales Volume (2015-2020)
3.12.1 Rest of the World Therapeutic Nuclear Medicines Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Therapeutic Nuclear Medicines Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Therapeutic Nuclear Medicines Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Therapeutic Nuclear Medicines Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Therapeutic Nuclear Medicines Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Therapeutic Nuclear Medicines Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Therapeutic Nuclear Medicines Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Therapeutic Nuclear Medicines Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Therapeutic Nuclear Medicines Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Therapeutic Nuclear Medicines Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Therapeutic Nuclear Medicines Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Therapeutic Nuclear Medicines Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Therapeutic Nuclear Medicines Sales Volume Market Share by Type (2015-2020)
14.2 Global Therapeutic Nuclear Medicines Sales Revenue Market Share by Type (2015-2020)
14.3 Global Therapeutic Nuclear Medicines Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Therapeutic Nuclear Medicines Consumption Volume by Application (2015-2020)
15.2 Global Therapeutic Nuclear Medicines Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Therapeutic Nuclear Medicines Business
16.1 Bayer
16.1.1 Bayer Company Profile
16.1.2 Bayer Therapeutic Nuclear Medicines Product Specification
16.1.3 Bayer Therapeutic Nuclear Medicines Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Lantheus
16.2.1 Lantheus Company Profile
16.2.2 Lantheus Therapeutic Nuclear Medicines Product Specification
16.2.3 Lantheus Therapeutic Nuclear Medicines Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Dongcheng
16.3.1 Dongcheng Company Profile
16.3.2 Dongcheng Therapeutic Nuclear Medicines Product Specification
16.3.3 Dongcheng Therapeutic Nuclear Medicines Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Novartis AG
16.4.1 Novartis AG Company Profile
16.4.2 Novartis AG Therapeutic Nuclear Medicines Product Specification
16.4.3 Novartis AG Therapeutic Nuclear Medicines Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 Jubilant DraxImage
16.5.1 Jubilant DraxImage Company Profile
16.5.2 Jubilant DraxImage Therapeutic Nuclear Medicines Product Specification
16.5.3 Jubilant DraxImage Therapeutic Nuclear Medicines Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 China Isotope & Radiation
16.6.1 China Isotope & Radiation Company Profile
16.6.2 China Isotope & Radiation Therapeutic Nuclear Medicines Product Specification
16.6.3 China Isotope & Radiation Therapeutic Nuclear Medicines Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 Progenics Pharmaceuticals
16.7.1 Progenics Pharmaceuticals Company Profile
16.7.2 Progenics Pharmaceuticals Therapeutic Nuclear Medicines Product Specification
16.7.3 Progenics Pharmaceuticals Therapeutic Nuclear Medicines Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 Curium Pharmaceuticals
16.8.1 Curium Pharmaceuticals Company Profile
16.8.2 Curium Pharmaceuticals Therapeutic Nuclear Medicines Product Specification
16.8.3 Curium Pharmaceuticals Therapeutic Nuclear Medicines Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.9 Q BioMed
16.9.1 Q BioMed Company Profile
16.9.2 Q BioMed Therapeutic Nuclear Medicines Product Specification
16.9.3 Q BioMed Therapeutic Nuclear Medicines Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.10 Spectrum Pharmaceuticals
16.10.1 Spectrum Pharmaceuticals Company Profile
16.10.2 Spectrum Pharmaceuticals Therapeutic Nuclear Medicines Product Specification
16.10.3 Spectrum Pharmaceuticals Therapeutic Nuclear Medicines Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.11 International Isotopes
16.11.1 International Isotopes Company Profile
16.11.2 International Isotopes Therapeutic Nuclear Medicines Product Specification
16.11.3 International Isotopes Therapeutic Nuclear Medicines Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Therapeutic Nuclear Medicines Manufacturing Cost Analysis
17.1 Therapeutic Nuclear Medicines Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Therapeutic Nuclear Medicines
17.4 Therapeutic Nuclear Medicines Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Therapeutic Nuclear Medicines Distributors List
18.3 Therapeutic Nuclear Medicines Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Therapeutic Nuclear Medicines (2021-2026)
20.2 Global Forecasted Revenue of Therapeutic Nuclear Medicines (2021-2026)
20.3 Global Forecasted Price of Therapeutic Nuclear Medicines (2015-2026)
20.4 Global Forecasted Production of Therapeutic Nuclear Medicines by Region (2021-2026)
20.4.1 North America Therapeutic Nuclear Medicines Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Therapeutic Nuclear Medicines Production, Revenue Forecast (2021-2026)
20.4.3 Europe Therapeutic Nuclear Medicines Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Therapeutic Nuclear Medicines Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Therapeutic Nuclear Medicines Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Therapeutic Nuclear Medicines Production, Revenue Forecast (2021-2026)
20.4.7 Africa Therapeutic Nuclear Medicines Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Therapeutic Nuclear Medicines Production, Revenue Forecast (2021-2026)
20.4.9 South America Therapeutic Nuclear Medicines Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Therapeutic Nuclear Medicines Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Therapeutic Nuclear Medicines by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Therapeutic Nuclear Medicines by Country
21.2 East Asia Market Forecasted Consumption of Therapeutic Nuclear Medicines by Country
21.3 Europe Market Forecasted Consumption of Therapeutic Nuclear Medicines by Countriy
21.4 South Asia Forecasted Consumption of Therapeutic Nuclear Medicines by Country
21.5 Southeast Asia Forecasted Consumption of Therapeutic Nuclear Medicines by Country
21.6 Middle East Forecasted Consumption of Therapeutic Nuclear Medicines by Country
21.7 Africa Forecasted Consumption of Therapeutic Nuclear Medicines by Country
21.8 Oceania Forecasted Consumption of Therapeutic Nuclear Medicines by Country
21.9 South America Forecasted Consumption of Therapeutic Nuclear Medicines by Country
21.10 Rest of the world Forecasted Consumption of Therapeutic Nuclear Medicines by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer